|
|
Blood, 15 May 2007, Vol. 109, No. 10, pp. 4424-4431.
Prepublished online as a Blood First Edition Paper on January 25, 2007; DOI 10.1182/blood-2006-11-056648.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status
C. Ian Mockridge1,3,
Kathleen N. Potter1,3,
Isla Wheatley1,3,
Louise A. Neville1,3,
Graham Packham2,3, and
Freda K. Stevenson1,3
1 Molecular Immunology Group, Tenovus Laboratory;
2 Cancer Research United Kingdom Clinical Centre; and
3 Cancer Sciences Division, School of Medicine, University of Southampton, Southampton General Hospital, United Kingdom
The 2 subsets of chronic lymphocytic leukemia (CLL), of worse or better prognosis, likely derive from pre-GC unmutated B cells, or post-GC mutated B cells, respectively. Different clinical behavior could relate to the ability of tumor cells to respond to surface (sIg)–mediated signals. Unmutated cases (U-CLL) have an increased ability to phosphorylate p72Syk in response to sIgM ligation compared to mutated cases (M-CLL). We now confirm and further investigate this differential signaling in a large cohort by [Ca2+]i mobilization. Cases responding to sIgM ligation express higher levels of CD38, ZAP-70, and sIgM. However, CD38 does not influence signaling in vitro or associate with response in bimodal CD38-expressing cases. Similarly, ZAP-70 expression is not required for response in either U-CLL or M-CLL. Strikingly, partially or completely anergized sIgM responses from each subset can recover both sIgM expression and signal capacity spontaneously in vitro or following capping/endocytosis. This provides direct evidence for engagement of putative antigen in vivo. Signaling via sIgD differs markedly being almost universally positive in both U-CLL and M-CLL, with no association with CD38 or ZAP-70 expression. Downstream signaling pathways, therefore, appear intact in CLL, locating anergy to sIgM, mainly in M-CLL. Integration of differential isotype-specific effects mediated by (auto)antigen may determine tumor behavior.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. P. Quiroga, K. Balakrishnan, A. V. Kurtova, M. Sivina, M. J. Keating, W. G. Wierda, V. Gandhi, and J. A. Burger
B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406
Blood,
July 30, 2009;
114(5):
1029 - 1037.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Guarini, S. Chiaretti, S. Tavolaro, R. Maggio, N. Peragine, F. Citarella, M. R. Ricciardi, S. Santangelo, M. Marinelli, M. S. De Propris, et al.
BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgVH unmutated chronic lymphocytic leukemia (CLL) cells
Blood,
August 1, 2008;
112(3):
782 - 792.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Muzio, B. Apollonio, C. Scielzo, M. Frenquelli, I. Vandoni, V. Boussiotis, F. Caligaris-Cappio, and P. Ghia
Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy
Blood,
July 1, 2008;
112(1):
188 - 195.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Chen, L. Huynh, J. Apgar, L. Tang, L. Rassenti, A. Weiss, and T. J. Kipps
ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia
Blood,
March 1, 2008;
111(5):
2685 - 2692.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G. Longo, L. Laurenti, S. Gobessi, S. Sica, G. Leone, and D. G. Efremov
The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells
Blood,
January 15, 2008;
111(2):
846 - 855.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
